

## Patent Claims 1 to 12

1. Use of a lipopeptide or lipoprotein of the following general formula

wherein

 $R_1$  and  $R_2$ , which may be identical or different, mean a  $C_{7\text{--}25}$ alkyl,  $C_{7-25}$ -alkeny) or  $C_{7-25}$ -alkinyl,

X means S, O or CH2,

 $Z_1$  and  $Z_2$ , which may be identical or different from each other, mean A or methyl,

W means CO or  $S(0)_n$  (for n = 1 or 2) and

Y means a physiologically acceptable amino acid sequence consisting of 1 to 25 amino acid residues and

#0754 P. 023

BOETERS & BAUER

S3653 68 64+ 74:71 1005'IAM. E0

the asymmetric carbon atom marked with \* has the absolute S-configuration if X = S (sulfur) for the production of a pharmaceutical preparation for wound treatment of animals or humans.

Cent B1

- 2. Use according to claim 1 characterized in that Y means a physiologically acceptable amino acid sequence consisting of 1 to 25 amino acids.
- 3. Use according to claim 1 characterized in that Y means an amino acid sequence selected from the group consisting of:
- (i) amino acid sequence which does not impair the water solubility of the lipopeptide or lipoprotein;
- (ii) GQTNT
- (iii) SKKKK
- (iv) GNNDESNISFKEK
- (v) GQTDNNSSQSQQPGSGTTNT whereby in the amino acid sequences (ii), (iii), (iv) and (v) individual amino acids may be omitted or exchanged.
- 4. Use according to any of the preceding claims, wherein the  $C_{7-25}$ -alkyl,  $C_{7-25}$ -alkenyl or  $C_{7-25}$ -alkinyl is  $C_{15}$ -alkyl,  $C_{15}$ -alkenyl or  $C_{15}$ -alkinyl.
- 5. Use according to any of the preceding claims, wherein the double bond(s) of the  $C_{7-25}$ -alkenyl residue has (have) cisconfiguration.
- 6. Use of a physiologically acceptable lipopeptide or lipoprotein, which is provided N-terminally with a dihydroxypropyl-cystein group with two ester-like linked optionally long-chain fatty acids which may be identical or different, for

the production of a pharmaceutical preparation for wound treatment of animals or humans.

- 7. Use of a lipopeptide or lipoprotein obtainable from a My-coplasma clone for wound treatment of animals or humans.
- 8. Use according to claim 7, characterized in that the lipopeptide or lipoprotein is obtainable from a Mycoplasma fermentans clone.
- 9. Use according to any of the preceding claims, wherein the lipopeptide or lipoprotein is water-soluble or amphoteric.
- 10. Use according to any of the preceding claims of a lipopeptide or lipoprotein selected from the group consisting of:
- (i) S-[2,3-bispalmitoyloxy-(2RS)-propyl]cysteinyl-GQTNT
- (ii) S-[2,3-bispalmitoyloxy-(2RS)-propyl]cysteinyl-SKKK
- (iii) S-[2,3-bispalmitoyloxy-(2RS)-propyl]cysteinyl-GNNDESNISFKEK
- (iv) S-(2,3-bispalmitoyloxy-(2S)-propyl]cysteinyl-GNNDESNISFKEK
- (v) S-[2,3-bispalmitoyloxypropyl]cysteinyl-GQTDNNSSQSQQPGSGTTNT.



11. Use according to any of the preceding claims, wherein the lipopeptide or lipoprotein can be provided in form of a solution for epicutaneous application, an injection solution, an ointment, a lotion, an aqueous suspension, a patch impregnated or coated therewith, encapsulated in liposomes or coupled to carrier polymers which are biologically degradable.

12. Use according to any of the preceding claims, wherein the wounds are wounds resulting from lesions or surgery, chronically infected wounds, burns, chronical ulcera or ulcus venosum or wounds of patients who are corpulent or diabetics or have been subjected to a radiation therapy or chemotherapy.